Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing innovative therapies for heart diseases. The company's primary objective is to research and produce anti-inflammatory and anti-fibrotic treatments aimed at addressing severe cardiovascular conditions such as acute myocarditis and chronic heart failure. Cardiol's research mainly involves utilizing cannabidiol (CBD), a compound derived from cannabis, in formulating therapies that could potentially mitigate inflammation and prevent cardiac fibrosis. These treatments are designed to meet the unmet medical needs of patients suffering from cardiac-related functions, positioning the company within the biotechnology and healthcare industries. Cardiol Therapeutics Inc. contributes to the pharmaceutical sector by offering novel approaches that could redefine existing therapeutic protocols for heart disease treatment. Headquartered in Oakville, Ontario, the company is recognized for its commitment to rigorous scientific research and development, aiming to make significant strides in global cardiovascular medicine.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. David G. Elsley MBA

Employees

18

Headquarters

Oakville, ON, Canada

Website

www.cardiolrx.com